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Abstract: In this study, we used oxazinethione as a perfect precursor to synthesize new pyrimidine
and pyrazole derivatives with potent biological activities. Biological activities were determined
for all compounds against A. flavus, E. coli, S. aureus, and F. moniliform. Compounds 3, 4a-b, and 5
exhibited higher activities toward A. flavus, E. coli, S. aureus, and F. moniliform; this was indicated
through the MIC (minimum inhibitory concentration). At the same time, anticancer activities were
determined through four cell lines, Ovcar-3, Hela, MCF-7, and LCC-MMk. The results obtained
indicated that compound 5 was the most potent compound for both cell lines. Molecular docking
was studied by the MOE (molecular operating environment). The in silico ADME of compounds 2
and 5 showed good pharmacokinetic properties. The present research strengthens the applicability
of these compounds as encouraging anticancer and antibacterial drugs. Moreover, JAGUAR module
MD simulations were carried out at about 100 ns. In addition, spectroscopic studies were carried out
to establish the reactions of the synthesized structure derivatives.
Keywords: oxazines; pyrimidine; pyrazole; one-pot synthesis; molecular docking; ADME
1. Introduction
Oxazinethione is a bright nucleus in many pharmacological studies and applications.
One of oxazinethione is compound 1a-b which was prepared in our laboratory Figure 1.
Therefore, oxazine derivatives were studied as an antimicrobial with promising results [1];
these nuclei. In addition, some derivatives of oxazinethione have been used as an anticancer,
anti-inflammatory, analgesic, and many pharmacological activities [2,3].
Moreover, oxazinethione was reported to have antimicrobial activities [4]. The new
value in this research is the use of oxazine as a precursor for pyrimidine derivatives, and
these new derivatives have essential biological activities [5]. An easy way of synthesizing
and studying the biological activities of oxazine pyrimidine and oxazine pyrazole deriva-
tives was reported with promising results [6]. Many drugs containing the oxazinethione
moiety serve a different medical purpose, such as Timolol as an antihypertensive drug
and reboxetine, which treats significant depression. More than 200 pyrimidine derivatives
have been used as antimicrobial agents with other mono-, di-, tri-, and tetrasubstituted
classes [7]. In addition, in vitro studies of the antimicrobial activities of pyrimidine deriva-
tives can facilitate the development of more potent and effective antimicrobial agents [8].
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Some pyrimidines, especially minoxidil, are vasodilating antihypertensive agents used for
resistant hypertension that is symptomatic or has caused end-organ damage, which also
acted on prostaglandin G/H synthase [9]. Our new research describes oxazinethione as a
precursor, developing pyrimidine and pyrazole derivatives as antimicrobial and anticancer
drugs, and they were tested against four cell lines, Ovcar-3 (ovarian), Hela (cervical Hela),
MCF-7 (breast), and LCC-MMk (normal cell). Molecular docking was used to predict
and prove the biological studies obtained by MOE, validated by general proteins using
JAGUAR modules. ADMET studies and molecular dynamic studies indicated the predic-
tion and validation of the activity of the synthesized compounds. The use of computational
studies is one of the modern techniques that help describe the pharmacological properties
of the synthesized compounds. The consequence of the present research strengthens the
applicability of these compounds as encouraging anticancer and antibacterial drugs that
could help medicinal chemists and pharmaceuticals further design and synthesize more
effective drug candidates [10–16].
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2. Results and Discussion  
2.1. Chemistry 
Sensitized oxazinethione [1] is the precursor of the new pyrimidine derivatives: 
(Schemes 1 and 2), pyrazolone derivatives, oxazinethione. 
Oxazinethione derivative (1a) reacted with urea and thiourea in n-butanol by boiling, 
which gave 2-(tetrabromophthalimidomethyl-6-phenyl-5-cyano-1,3-oxazino[4,5-e]-1,3-
pyrimidine-3-[H]-2,4-dione (2a) and 2-(tetrabromophthalimidomethyl-6-phenyl-5-cyano-
1,3-oxazino[4,5-e]-1,3-pyrimidine-3-[H]-2-thione-4-one (2b). The structures of both (2a 
and 2b) were proved by analytical data, and the IR spectra of (2a) and (2b) exhibited ab-
sorptions at 1720–1710 cm−1 (CO), 2230–2220 cm−1 (CN), 1200–1190 cm−1 (CS), and 3380–
3370 cm−1 (NH). The 1HNMR of 2b showed signals at δ ppm 3.7 (2H, CH2), 7.2–7.8 (6H, 
AH+NH), and (1H, phCH) J = 5.3. Compound (1a) also reacted with hydrazine hydrate in 
boiling n-butanol, resulting in 2-(tetrabromophalimidmethyl)-6-phenyl-5-yano-1,3-oxa-
zino[4,5-d]-1,2-pyrazole2[H]-3-one (3), Scheme 2. 
The compound (3) structure was proved by analytical data, and the IR spectra exhib-
ited absorptions at 1715 cm−1 as CO, 2205 cm−1 as the presence of CN, and 3154–3350 cm−1 
as the presence of NH. Oxazinethione derivative (1b) reacted with urea and thiourea in n-
butanol with boiling 2-(tetrabromophthalimidomethyl-6-phenyl-5-cyano-1,3-oxazino[4,5-
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Sensitized oxazinethione [1] is the precursor of the new pyrimidine derivatives:
(Schemes 1 and 2), pyrazolone derivatives, oxazinethione.
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Analytical data proved the structure of compounds (4a-b), and the IR spectra of 4a 
and 4b exhibited absorptions at 1278 cm−1 (CS), 2260 cm−1 (CN), 3378 cm−1 (NH), and 1780 
and 1720 cm−1 (CO). The mass spectrum of (4b) represented a sharp characteristic molec-
ular ion peak at m/z 758. Compound (1b) also reacted with hydrazine hydrate in boiling 
n-butanol, resulting in 2-(tetrabromophalimidmethyl)-6-phenyl-5-yano-1,3-oxazino[4,5-
d]-1,2-pyrazole2[H]-3-imide (5), Scheme 2. Analytical data proved the structure of com-
pound (5); it showed the IR spectrum at 3350–3310 cm−1 (N.H.) and 2360 cm−1 (CN), in 
addition to the coupling of carbonyl bands of cyclic imide at 1780 and 1730 cm−1. 1HNMR 
showed characteristic signals at (δ ppm), 3.2 (H, CH2), 7.2–7.8 (7H, ArH, and 2NH), and 
(1H, PCH). All the mechanisms of the reactions are included in Tables. While Figure 2 
represents the structures of the synthesized compounds. 
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1720–1710 cm−1 (CO), 2230–2220 cm−1 (CN), 1200–1190 cm−1 (CS), and 3380–3370 cm−1
(NH). The 1HNMR of 2b showed signals at δ ppm 3.7 (2H, CH2), 7.2–7.8 (6H, AH+NH),
and (1H, phCH) J = 5.3. Compound (1a) also reacted with hydrazine hydrate in boiling
n-butanol, resulting in 2-(tetrabromophalimidmethyl)-6-phenyl-5-yano-1,3-oxazino[4,5-d]-
1,2-pyrazole2[H]-3-one (3), Scheme 2.
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hydrate in boiling n-butanol, resulting in 2-(tetrabromophalimidmethyl)-6-phenyl-5-yano-
1,3-oxazino[4,5-d]-1,2-pyrazole2[H]-3-imide (5), Scheme 2. Analytical data proved the
structure of compound (5); it showed the IR spectru at 3350–3310 cm−1 (N.H.) and
2360 cm−1 (CN), in addition to the coupling of carbonyl bands of cyclic imide at 1780 and
1730 cm−1. 1HNMR showed characteristic signals at (δ ppm), 3.2 (H, CH2), 7.2–7.8 (7H,
ArH, and 2NH), and (1H, PCH). All the mechanisms of the reactions are included in Tables.
While Figure 2 represents the structures of the synthesized compounds.
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2.2. Biology
2.2.1. Antimicrobial Studies
All the prepared compounds were subjected to investigations regarding Gram-positive
and Gram-negative bacteria [17–20]. From the obtained biological data in Table 1, an
evident elevated level of activity was demonstrated for derivatives 2a, 2b, 3, 4a, 4b, and 5
in evaluating A. flavus, with similar behavior being detected with 3, 4a, and 5; 2a, 3, 4a, 4b,
and 5 exhibited activity toward E. coli, while 2a, 2b, 3, 4b, and 5 exhibited activity toward S.
aureus. Moreover, all of them were active in the assessment with F. moniliform. The results
are summarized in Table 1.




A. flavus E. coli S. aureus F. moniliform
A Mic A Mic A Mic A Mic
2a - - - - + 125 + 125
2b - - + 250 ++ 250 + 125
3 + 125 + 12 + 125 + 125
4a +++ 250 + 250 - - + 250
4b - - + 250 ++ 250 + 125
5 +++ 250 ++ 250 ++ 250 + 250
The zone width of inhibition indicates the potency of antimicrobial activity; (-) no activity, (+) mild activity with diameter zone of
(0.5–0.7 cm), (++) moderate activity with diameter zone of (1.1–1.2 cm); (+++) marked with diameter zone of (1.6–1.8 cm).
2.2.2. Anticancer Studies
All the synthesized compounds were tested against three cell lines, MCF-7 for breast
cancer, Ovcar-3 for ovarian cancer, and Hela for cervical cancer. In addition, all the results
obtained were compared and validated to the LCC-MK2 normal cell line. The results
obtained in Table 2 indicated that compounds 4b and 5 are the most potent compounds. The
results obtained are illustrated in Table 2, and graphical statistical analysis is represented
in Figure 3. Compound 5 showed to be the most potent and effective for the three cell lines,
which posed IC50 values of 12.31, 5.69, and 10.05 µg/mL for MCF-7, HeLa, and ovcar-3,
respectively. On the other hand, the IC50 of LCC-MK2 showed that these compounds are
of moderate safety as most of the IC50 values are less than 200 µg/mL.
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Table 2. IC50 for tested compounds against different cell lines, in µg/mL.
Cpd. MCF-7 Hela Ovcar-3 LCC-MK2
IC50 ±SD IC50 +SD IC50 ±SD IC50 ±SD
2b 13.82 0.26 22.81 2.31 15.22 0.70 89.34 23.56
3 15.49 4.59 9.14 0.06 14.57 1.94 206.50 59.36
4a 21.70 3.09 12.88 0.10 15.86 0.50 68.91 2.37
4b 16.56 0.09 14.76 0.38 11.23 1.75 170.40 0.00
5 12.31 3.90 5.69 0.14 10.05 1.18 190.93 53.80








Figure 3. Inhibition and IC50 of selected compounds in DMSO solutions toward MCF-7, Hela, Ovcar-3, and LLC-MK2 cell 
lines. 
  
Figure 3. Inhibition and IC50 of selected compounds in DMSO solutions toward MCF-7, Hela,
Ovcar-3, and LLC-MK2 cell lines.
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2.3. Computational Studies
2.3.1. Molecular Modeling Studies Using MOE
Molecular docking is a computational software routinely used for understanding
the protein–receptor interaction with complexes [10,21]. The docking process was carried
out by simulating the interaction of the prepared compounds with three types of protein-
receptors: MCF-7 breast (PDB = 3 KRR), Ovcar-3 Ovarian cancer (PDB = 3 W2S), and
HeLa caspase (PDB = 3 V266), which have been selected according to the literature and
previous studies [22–24]. The docking score energies of MCF-7 (PDB = 3 KRR), HeLa
caspase (PDB = 3 V266), and Ovarian cancer (PDB = 3 W2S) are represented in Tables 3–5,
respectively, and indicates that compound 5 is the most potent. All 3D and 2D interactions
for the three targets are illustrated in Figures 2–4, respectively. The docking interactions of
MCF-7 (PDB = 3 KRR), HeLa caspase (PDB = 3 V266), and Ovarian cancer (PDB = 3 W2S)
are illustrated in Tables 6–8, respectively.
Table 3. Docking score and energies of all compounds with MCF-7 breast docking result of
“3 KRR” protein.
Comp. S rmsd_refine E_conf E_place E_score1 E_refine E_score2
2a
−8.43 2.30 −212.78 −81.54 −12.39 −35.32 −8.43
−8.17 1.29 −203.26 −82.90 −12.82 −40.22 −8.17
−8.10 2.25 −194.54 −88.98 −11.17 −43.54 −8.10
−8.09 1.36 −206.26 −72.74 −11.47 −33.41 −8.09
−7.85 1.91 −207.36 −67.90 −11.13 −31.42 −7.85
3
−8.09 1.54 −65.96 −77.00 −11.74 −34.65 −8.09
−8.28 1.97 −65.67 −53.76 −11.49 −28.68 −8.28
−8.20 2.42 −72.23 −86.55 −10.34 −37.10 −8.20
−8.15 1.66 −76.70 −119.31 −12.66 −48.38 −8.15
−7.88 2.07 −76.97 −92.42 −11.00 −46.31 −7.88
4a
−8.06 2.27 −215.68 −87.53 −10.78 −39.39 −8.06
−7.90 1.10 −212.32 −85.86 −10.69 −34.31 −7.90
−7.89 1.12 −214.27 −94.83 −11.37 −33.22 −7.89
−7.83 1.99 −210.89 −55.41 −10.83 −38.45 −7.83
−7.80 1.63 −210.48 −78.77 −11.53 −35.98 −7.80
4b
−8.10 2.64 −192.81 −56.79 −9.91 −40.36 −8.10
−7.75 1.64 −193.11 −82.44 −11.96 −34.88 −7.75
−7.69 1.14 −191.25 −67.17 −11.13 −43.84 −7.69
−7.67 2.93 −194.16 −84.16 −11.16 −44.49 −7.67
−7.46 4.17 −177.93 −69.28 −10.53 −21.68 −7.46
5
−8.45 2.08 −76.73 −76.05 −11.80 −35.78 −8.45
−8.27 1.65 −76.64 −60.46 −10.32 −30.34 −8.27
−8.15 2.53 −86.74 −63.97 −10.31 −47.86 −8.15
−8.09 2.16 −84.21 −75.90 −11.73 −45.81 −8.09
−7.97 2.28 −84.96 −68.94 −10.87 −35.63 −7.97
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Table 4. Docking score and energies of all compounds with HeLa caspase “3 V266” protein.
Comp. S rmsd_refine E_conf E_place E_score1 E_refine E_score2
2a
−6.22 1.41 −215.59 −55.68 −10.19 −37.97 −6.22
−7.18 2.38 −215.00 −39.36 −10.47 −39.33 −7.18
−6.71 2.48 −214.45 −85.06 −9.92 −39.51 −6.71
−6.67 1.86 −214.32 −48.53 −10.00 −31.84 −6.67
−6.49 1.20 −218.06 −81.95 −11.05 −28.54 −6.49
3
−7.45 1.46 −64.61 −63.24 −9.74 −37.05 −7.45
−6.42 1.66 −71.66 −58.22 −10.24 −29.76 −6.42
−6.40 1.50 −73.19 −82.55 −11.59 −36.54 −6.40
−6.39 2.08 −74.87 −67.51 −10.52 −35.25 −6.39
−6.38 1.98 −67.73 −73.49 −11.36 −28.50 −6.38
4a
−6.74 1.48 −224.62 −96.40 −10.43 −30.40 −6.74
−6.59 4.54 −223.62 −41.68 −11.62 −34.24 −6.59
−6.51 1.69 −222.06 −46.45 −10.35 −31.55 −6.51
−6.45 1.28 −217.10 −42.55 −9.81 −27.20 −6.45
−6.43 3.94 −223.58 −74.74 −10.32 −33.29 −6.43
4a
−7.15 2.11 −193.36 −72.65 −10.43 −38.75 −7.15
−6.80 1.21 −201.45 −92.81 −10.69 −34.58 −6.80
−6.61 4.02 −201.54 −68.46 −9.64 −36.48 −6.61
−6.61 2.94 −199.69 −45.26 −9.68 −34.36 −6.61
−6.44 1.98 −194.51 −61.61 −10.37 −31.49 −6.44
5
−7.91 2.58 −81.90 −45.97 −9.62 −43.31 −7.91
−6.49 1.61 −83.08 −50.78 −9.51 −42.46 −6.49
−6.39 1.52 −82.96 −67.06 −10.80 −34.79 −6.39
−6.37 2.03 −85.56 −80.15 −9.61 −34.14 −6.37
−6.26 2.93 −86.09 −61.42 −9.86 −31.70 −6.26
Table 5. Docking score and energies of all compounds with ovarian “3 W2S” protein.
Comp. S rmsd_refine E_conf E_place E_score1 E_refine E_score2
2a
−7.70 1.60 −219.01 −77.08 −10.27 −44.05 −7.70
−7.19 2.26 −218.05 −78.25 −9.69 −39.51 −7.19
−7.14 2.42 −215.81 −77.27 −10.93 −40.10 −7.14
−7.00 1.80 −200.88 −62.91 −9.93 −25.82 −7.00
−6.96 1.70 −224.02 −50.21 −9.71 −36.41 −6.96
3
−7.39 1.59 −70.23 −91.55 −9.50 −43.12 −7.39
−7.54 2.85 −73.44 −84.32 −10.71 −45.10 −7.54
−7.46 3.09 −78.20 −44.13 −10.22 −45.39 −7.46
−7.21 2.26 −78.10 −57.97 −9.53 −45.34 −7.21
−7.12 1.23 −70.06 −60.35 −9.94 −34.02 −7.12
4a
−7.66 1.10 −228.66 −99.53 −10.21 −44.05 −7.66
−7.66 1.75 −214.85 −88.63 −10.97 −41.02 −7.66
−7.06 1.13 −223.12 −92.78 −10.98 −34.17 −7.06
−7.06 2.36 −205.71 −78.95 −9.73 −33.29 −7.06
−6.74 1.14 −221.63 −46.92 −9.61 −32.15 −6.74
4b
−8.38 2.98 −201.86 −89.52 −10.94 −38.96 −8.38
−7.36 1.18 −199.20 −93.88 −11.48 −39.58 −7.36
−7.29 1.10 −205.78 −110.63 −11.67 −40.47 −7.29
−7.07 2.36 −192.78 −64.95 −10.54 −39.50 −7.07
−6.96 1.94 −196.57 −78.63 −10.34 −33.65 −6.96
5
−8.77 2.24 −86.58 −74.44 −12.15 −50.19 −8.77
−7.69 1.78 −87.46 −83.46 −9.87 −39.94 −7.69
−7.54 2.64 −73.58 −50.75 −10.56 −40.73 −7.54
−7.46 1.71 −81.62 −70.61 −10.04 −40.33 −7.46
−7.45 1.65 −88.79 −67.97 −10.21 −42.42 −7.45
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Table 6. Docking interaction of all compounds with MCF-7 breast docking result of “3 KRR” protein.
Compound Ligand Receptor Interaction Distance E (kcal/mol)
2a O 13 CA GLY 858 H-acceptor 3.31 −1.6
3 N 44 NH1 ARG 980 H-acceptor 3.22 −1.1
4a
N 10 O LYS 857 H-donor 2.95 −1.2
N 13 O LYS 857 H-donor 2.84 −0.5
5-ring CB LEU 855 pi-H 4.28 −0.7
6-ring CB LEU 855 pi-H 4.32 −0.7
4b
N 10 O LYS 857 H-donor 2.94 −0.3
5-ring CB LEU 855 pi-H 4.28 −0.4
6-ring CB LEU 855 pi-H 4.32 −0.4
5 N 43 NH1 ARG 980 H-acceptor 3.30 −1.9
Table 7. Docking interaction of all compounds with HeLa caspase “3 V266” protein.
Compound Ligand Receptor Interaction Distance E (kcal/mol)
2a
Br 26 O GLY 122 (A) H-donor 3.37 −2.5
6-ring NE ARG 64 (A) pi-cation 4.79 −0.9
6-ring NE ARG 207 (A) pi-cation 3.98 −0.9
6-ring NH1 ARG 207 (A) pi-cation 3.28 −0.6
3
C 27 SG CYS 163 (A) H-donor 3.85 −0.5
6-ring NE ARG 64 (A) pi-cation 4.43 −1.9
4a
O 15 NE ARG 64 (A) H-acceptor 3.36 −1.0
O 15 NH2 ARG 64 (A) H-acceptor 3.33 −2.4
O 15 NE ARG 207 (A) H-acceptor 3.10 −1.6
4b
Br 28 O GLY 122 (A) H-donor 3.44 −0.5
6-ring SG CYS 163 (A) pi-H 4.18 −0.7
6-ring NE ARG 207 (A) pi-cation 3.71 −1.1
5
Br 15 O GLY 60 (A) H-donor 3.50 −0.8
O 30 CA TRP 206 (A) H-acceptor 3.42 −0.5
O 30 N ARG 207 (A) H-acceptor 3.14 −2.4
6-ring NE ARG 64 (A) pi-cation 4.89 −0.9
Table 8. Docking interaction of all compounds with ovarian “3 W2S” protein.
Compound Ligand Receptor Interaction Distance E (kcal/mol)
2a
C 30 O ARG 841 (A) H-donor 3.24 −0.5
6-ring CD ARG 841 (A) pi-H 3.75 −1.0
3 No measurable interactions
4a 6-ring CD ARG 841 (A) pi-H 3.92 −0.7
4b
C 31 O ARG 841 (A) H-donor 3.38 −0.8
6-ring CG1 VAL 726 (A) pi-H 4.50 −0.5
6-ring CD ARG 841 (A) pi-H 3.74 −0.7
5
N 24 O GLY 724 (A) H-donor 2.85 −2.8
N 43 NZ LYS 745 (A) H-acceptor 3.00 −10.2
6-ring CA GLY 721 (A) pi-H 4.24 −0.9
6-ring N ALA 722 (A) pi-H 4.79 −0.7
From Table 3, the docking score energies of the synthesized compounds 2a, 3, 4a,
4b, and 5 with 3 KRR were −8.43, −8.05, −8.06, −8.1, and −8.45, respectively. From
Table 4, the docking score energies of the synthesized compounds 2a, 3, 4a, 4b, and 5 with
V266 were −6.22, −7.45, −6.74, −7.15, and −7.41, respectively. Finally, from Table 5, the
docking score energies of the synthesized compounds 2a, 3, 4a, 4b, and 5 with 2 W2S were
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−7.7, −7.39, −7.66, −8.38, and −8.77, respectively. These results indicate that the most
potent compound for the three proteins was compound 5, while compound 5 was most
potent to 2 W2S.
From Figure 4, one can notice in the case of the MCF-7 target receptor that the docking
pose of the 3 KRR protein showed that the main contribution of the activity belonged
to the interaction of our compounds with the two amino acids Arg 880 and Gly 858
by a nitrogen atom of the cyanide group and carbonyl group in compounds 2a and 5.
Meanwhile, from Figure 5, in the HeLa caspase3 target receptor and the docking pose of
V266 protein, one can also notice that the main contribution to the activity that belonged to
the interaction of our compounds with the amino acids Arg 64, Arg 207, Trp206, and Gly
60 was by one of a benzene ring, carbonyl group, and bromine atom, respectively, which
were represented in compound 5. Finally, from Figure 6, in the ovarian 3 W2S protein, the
main contribution of the activity was the interaction with our compounds with the three
amino acids Gly 721, Ala 722, and Lys 745 by one of a benzene ring and cyano group. These
results of docking interactions for the different proteins were represented in compound
5, as shown in Tables 6–8, respectively.
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2.3.2. ADME and Pharmacophore Studies 
ADME (absorption, distribution, metabolism, and excretion), including drug-like-
ness analysis, are essential in drug discovery, which accommodates the reasonable deci-
sion-making on whether or not inhibitors can be used in a biological system [21,25]. A 
potent antagonistic interaction of inhibitors with a receptor protein or enzyme cannot 
guarantee the ability of an inhibitor as a drug; therefore, ADME assessment is essential in 
drug development. Inhibitors with lower ADME properties and high toxicity effects on 
the biological systems are often the dominant explanation of most failed medicines in the 
clinical phase of experiments. 
From Figure 7, from the output of some ADME and drug-likeness properties shown 
in Tables 9–11, it was observed that compounds 2b to 5 molecules have one or two viola-
tions of Lipinski’s rule, and the first violated is the molecular weight rule with 663.07–
759.02 g/mol. The drug-likeness parameters are related to the aqueous solubility and in-
testinal permeability, determining the first step of oral bioavailability [25]. The results also 
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2.3.2. ADME and Pharmacophore Studies
ADME (absorption, distribution, metabolism, and excretion), including drug-likeness
analysis, are essential in drug discovery, which accommodates the reasonable decision-
making on whether or not inhibitors can be used in a biological system [21,25]. A potent
antagonistic interaction of inhibitors with a receptor protein or enzyme cannot guarantee
the ability of an inhibitor as a drug; therefore, ADME assessment is essential in drug
development. Inhibitors with lower ADME properties and high toxicity effects on the
biological systems are often the dominant explanation of most failed medicines in the
clinical phase of experiments.
From Figure 7, from the output of some ADME and drug-likeness properties shown
in Tables 9–11, it was observed that compounds 2b to 5 molecules have one or two
violations of Lipinski’s rule, and the first violated is the molecular weight rule with
663.07–759.02 g/mol. The drug-likeness parameters are related to the aqueous solubil-
ity and intestinal permeability, determining the first step of oral bioavailability [25]. The
results also showed good pharmacokinetic properties in which compounds 2b and 5 have
high gastrointestinal absorption.
Table 9. Physicochemical Properties.
Comp. 2b 3 4a 4b 5
Formula C22H9Br4N5O4S C21H10Br4N6O3 C22H11Br3N6O4 C22H11Br3N6O3S C21H9Br4N5O4
Molecular weight 759.02 g/mol 713.96 g/mol 663.07 g/mol 679.14 g/mol 714.94 g/mol
Num. heavy atoms 36 34 35 35 34
Num. arom. heavy
atoms 12 12 12 12 12
Fraction Csp3 0.14 0.14 0.14 0.14 0.14
Num. rotatable
bonds 3 3 3 3 3
Num. H-bond
acceptors 7 7 8 7 7
Num. H-bond
donors 1 2 2 2 1
Molar Refractivity 160.73 151.53 149.22 156.42 148.13
TPSA 156.31 Å2 131.00 Å2 148.07 Å2 163.09 Å2 124.22 Å2
Lipophilicity
Log Po/w (iLOGP) 2.81 2.19 2.09 2.50 2.40
Log Po/w
(XLOGP3) 4.53 4.14 3.33 3.93 4.05
Log Po/w (WLOGP) 2.98 3.06 2.50 2.67 2.61
Log Po/w (MLOGP) 3.88 4.56 3.76 3.72 4.16
Log Po/w
(SILICOS-IT) 6.82 5.57 4.81 6.27 5.44
Consensus Log
Po/w
4.20 3.91 3.30 3.82 3.73
Water Solubility
Log S (ESOL) −7.45 −6.94 −6.10 −6.58 –6.89
Solubility 2.70 × 10
−5 mg/mL;
3.56 × 10−8 mol/L
8.24 × 10−5 mg/mL;
1.15 × 10−7 mol/L
5.21 × 10−5 mg/mL;
7.86 × 10−7 mol/L
1.78 × 10−5 mg/mL;
2.62 × 10−7 mol/L
9.27 × 10−5 mg/mL;
1.30 × 10−7 mol/L
Class Poorly soluble Poorly soluble Poorly soluble Poorly soluble Poorly soluble
Log S (Ali) −7.53 −6.60 −6.12 −7.05 −6.36
Solubility 2.22 × 10
−5 mg/mL;
2.92 × 10−8 mol/L
1.80 × 10−4 mg/mL;
2.52 × 10−7 mol/L
5.07 × 10−4 mg/mL;
7.65 × 10−7 mol/L
5.99 × 10−5 mg/mL;
8.83 × 10−8 mol/L
3.10 × 10−4 mg/mL;
4.34 × 10−7 mol/L
Class Poorly soluble Poorly soluble Poorly soluble Poorly soluble Poorly soluble
Log S (SILICOS-IT) −9.20 −9.04 −8.44 −8.62 −8.90
Solubility 4.76 × 10
−7 mg/mL;
6.27 × 10−10 mol/L
6.44 × 10−7 mg/mL;
9.02 × 10−10 mol/L
2.43 × 10−6 mg/mL;
3.66 × 10−9 mol/L
1.64 × 10−6 mg/mL;
2.42 × 10−9 mol/L
9.02 × 10−7 mg/mL;
1.26 × 10−9 mol/L
Class Poorly soluble Poorly soluble Poorly soluble Poorly soluble Poorly soluble
Pharmacokinetics
G.I. absorption Low High Low Low High
BBB permeant No No No No No
P-gp substrate No No No No No
CYP1A2 inhibitor Yes Yes No Yes Yes
CYP2C19 inhibitor No No No No No
CYP2C9 inhibitor No No No No No
CYP2D6 inhibitor No No No No No
CYP3A4 inhibitor No No No No No
Log Kp (skin
permeation) −7.71 cm/s −7.72 cm/s −7.98 cm/s −7.65 cm/s −7.79 cm/s
Molecules 2021, 26, 5482 14 of 24
Table 9. Cont.
Comp. 2b 3 4a 4b 5
Drug-likeness
Lipinski Yes; 1 violation: MW > 500 No; 2 violations: MW >500, MLOGP > 4.15
Yes; 1 violation: MW >
500
Yes; 1 violation: MW >
500
No; 2 violations: MW >
500, MLOGP > 4.15
Ghose No; 2 violations: MW > 480,MR > 130
No; 2 violations: MW >
480, MR > 130
No; 2 violations: MW >
480, MR > 130
No; 2 violations: MW >
480, MR > 130
No; 2 violations: MW >
480, MR > 130
Veber No; 1 violation: TPSA > 140 Yes No; 1 violation: TPSA >140
No; 1 violation: TPSA >
140 Yes
Egan No; 1 violation: TPSA >131.6 Yes
No; 1 violation: TPSA >
131.6
No; 1 violation: TPSA >
131.6 Yes
Muegge No; 2 violations: MW > 600,TPSA > 150
No; 1 violation: MW >
600
No; 1 violation: MW >
600
No; 2 violations: MW >
600, TPSA > 150
No; 1 violation: MW >
600
Bioavailability
Score 0.55 0.17 0.55 0.55 0.17
Medicinal Chemistry





















Lead-likeness No; 2 violations: MW > 350,XLOGP3 > 3.5
No; 2 violations: MW >
350, XLOGP3 > 3.5
No; 1 violation: MW >
350
No; 2 violations: MW >
350, XLOGP3 > 3.5
No; 2 violations: MW >
350, XLOGP3 > 3.5
Synthetic
accessibility 4.61 4.58 4.74 4.66 4.52
Table 10. Pharmacokinetic properties.
Model Name Pharmacokinetic Properties
Water solubility









83.586 84.559 80.732 82.507 84.596
Skin Permeability
(log Kp) −2.826 −2.8 −2.779 −2.782 −2.863
P-glycoprotein
substrate Yes Yes Yes Yes Yes
P-glycoprotein I
inhibitor Yes Yes Yes Yes Yes
P-glycoprotein II
inhibitor Yes Yes No No Yes
Table 11. Oral toxicity prediction results for all selected compounds.
Compound 2b 3 4a 4b 5
Predicted LD50 10,000 mg/kg 1000 mg/kg 1000 mg/kg 1168 mg/kg 300 mg/kg
Predicted
ToxicityClass * 6 4 4 4 3
Average similarity 34.04% 31.94% 35.06% 33.99% 32.14%
Prediction
accuracy: 23% 23% 23% 23% 23%
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2.3.3. Molecular Dynamics Studies and Validations of the Methods Used 
Analyses of the Interaction Patterns and Conformational Dynamics 
The protein selected for this study is listed in Table 12. The information regarding 
the active site of the proteins was collected from the literature [26–32]. The active site of 
the caspase-3 was observed at Met61, His121, Phe128, Cys163, Thr166, and Tyr204, while 
for cyclin-dependent kinase 2 (CDK2), it involved the residues Glu81, Phe82, Leu83, 
Asp86, and Lys89. Similarly, for the epidermal growth factor receptor (EGFR), the crystal 
structure showed that the binding site was present at Val726, Ala743, Lys745, Met766, 
Leu777, Leu788, Thr790, Met793, Asp800, Leu844, Thr854, and Asp855. The Human B-Raf 
Kinase includes Ala481, Lys483, Leu514, Ile527, Trp531, Cys532, Asp594, and Phe595 in 
the interaction cavity, while the Human Estrogen Receptor Ligand-Binding Domain has 
Glu353, Leu391, Arg394, Leu402, Ile424, His524, Leu525, and Leu540. There is varied in-
formation available regarding the human serum albumin (HSA) active site in the litera-
ture and databases. Therefore, all the residues were considered, while for Human topoi-
somerase I, the activity was observed at Arg488, Lys532, Arg590, and His632. The highest 
binding affinities were observed for the HSA against the 4a, 3, and 5 with the free energies 
of binding of −9.9 kcal/mol, −9.8 kcal/mol, and −9,3 kcal/mol, respectively. All three inhib-
itors showed similar residue patterns with the HSA, Figure 8. 
*
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2.3.3. Molecular Dynamics Studies and Validations of the Methods Used
Analyses of the Interaction Patterns and Conformational Dynamics
The protein selected for this study is listed in Table 12. The information regarding
the active site of the proteins was collected from the literature [26–32]. The active site
of the caspase-3 was observed at Met61, His121, Phe128, Cys163, Thr166, and Tyr204,
while for cyclin-dependent kinase 2 (CDK2), it involved the residues Glu81, Phe82, Leu83,
Asp86, and Lys89. Similarly, for the epidermal growth factor receptor (EGFR), the crystal
structure showed that the binding site was present at Val726, Ala743, Lys745, Met766,
Leu777, Leu788, Thr790, Met793, Asp800, Leu844, Thr854, and Asp855. The Human B-Raf
Kinase includes Ala481, Lys483, Leu514, Ile527, Trp531, Cys532, Asp594, and Phe595 in the
interaction cavity, while the Human Estrogen Receptor Ligand-Binding Domain has Glu353,
Leu391, Arg394, Leu402, Ile424, His524, Leu525, and Leu540. There is varied information
available regarding the human serum albumin (HSA) active site in the literature and
databases. Therefore, all the residues were considered, while for Human topoisomerase
I, the activity was observed at Arg488, Lys532, Arg590, and His632. The highest binding
affinities were observed for the HSA against the 4a, 3, and 5 with the free energies of
binding of −9.9 kcal/mol, −9.8 kcal/mol, and −9.3 kcal/mol, respectively. All three
inhibitors showed similar residue patterns with the HSA, Figure 8.
Table 12. List of virtual screening-based parameters for the selected drug targets against the studied anticancer inhibitors
(green color selected for MD simulations).
S. No Inhibitors


























1 2a −6.7 −8.7 −9.1 −8.5 −8.1 −8.6 −8.1
2 2b −6.7 −7.5 −8.2 −8.2 −8.2 −8.2 −7.9
3 3 −6.4 −8.0 −7.9 −9.2 −7.6 −9.8 −8.2
4 4a −6.6 −9.0 −8.1 −8.3 −8.5 −9.9 −8.1
5 4b −6.9 −7.4 −8.5 −8.5 −7.8 −8.4 −8.2
6 5 −6.7 −8.8 −8.9 −9.2 −7.7 −9.3 −8.2
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1 2a −6.7 −8.7 −9.1 −8.5 −8.1 −8.6 −8.1 
2 2b −6.7 −7.5 −8.2 −8.2 −8.2 −8.2 −7.9 
3 3 −6.4 −8.0 −7.9 −9.2 −7.6 −9.8  −8.2 
4 4a −6.6 −9.0 −8.1 −8.3 −8.5 −9.9 −8.1 
5 4b −6.9 −7.4 −8.5 −8.5 −7.8 −8.4 −8.2 
6 5 −6.7 −8.8 −8.9 −9.2 −7.7 −9.3 −8.2 
The HSA complexes with the highest binding affinities were selected for 100 ns mo-
lecular dynamics (MD) simulations. The root-mean-square deviation (RMSD) values pro-
vided the stability profile of the studied systems. One can observe that the 3a system 
achieves the highest stability with the values observed between 0.3 nm and 0.5 nm com-
pared to the other systems (Figure 9A). Estimating the degree of compactness of the stud-
ied systems in a radius of gyration (Rg) showed a similar degree of compactness for all 
the systems with values observed between 2.7 nm and 2.85 nm (Figure 9B). 
Furthermore, we inferred the bonding patterns from the hydrogen bonding and the 
calculated distances between the HSA and the studied systems. Inhibitor 5 showed the 
highest number of H-bonds of four with HSA, and inhibitors 4 and 3 showed three and 
two bonds, respectively (Figure 9C). One can also observe similar behavior for the calcu-
lated distances with the least distance of around 0.15 nm between the HSA and inhibitor 
5 (Figure 9D). Moreover, the MM/PBSA-based protocols were used to calculate the diverse 
interaction energies between the HSA and the studied inhibitors. Inhibitor 3 showed the 
highest binding energy of −375.922 kJ/mol, followed by inhibitors 5 and 4a (Table 13). 
These observations validated the experimental findings and showed that the studied in-
hibitors favorably bonded to the HSA proteins and may result in the limitation of the can-
cer proliferation by inhibiting the activities of the proteins. 
Figure 8. The result from docked complexes of HSA and studied inhibitors 3, 4a, and 5.
Molecules 2021, 26, 5482 17 of 24
The HSA complexes with the highest binding affinities were selected for 100 ns molec-
ular dynamics (MD) simulations. The root-mean-square deviation (RMSD) values provided
the stability profile of the studied systems. One can observe that the 3a system achieves
the highest stability with the values observed between 0.3 nm and 0.5 nm compared to the
other systems (Figure 9A). Estimating the degree of compactness of the studied systems in
a radius of gyration (Rg) showed a similar degree of compactness for all the systems with
values observed between 2.7 nm and 2.85 nm (Figure 9B).




Figure 9. The outputs generated from 100 ns MD simulations with (A) illustration of the changes in 
the RMSD values for the three studied systems, and (B) changes in the Rg values. (C) Graph depict-
ing the variation in the number of hydrogen bonds between HSA and docked inhibitors. (D) Curves 
showing the fluctuations in the calculated distances. 
Table 13. List of MM-PBSA-based generated energy parameters for the studied anticancer inhibitors 
complexed HSA. 
S. No Docked Complex 
MM-PBSA-Based Calculated Energies (kJ/mol) 
Van Der Waals Electrostatic SASA Binding e Energy 
1 3 −308.232 −22.682 −22.504 −375.922 
2 4a −244.065 −29.981 −23.239 −320.525 
3 5 −259.583 −41.077 −23.113 −346.887 
3. Methodology 
3.1. Chemistry 
All reactions were carried out with the exclusion of moisture. All solvents were dried. 
All melting points were uncorrected. The IR spectra were recorded as potassium bromide 
pellets on an Aldrich FT-IR spectrometer (Central lab at Faculty of Science, Benha, Ain 
Shams, and Cairo universities). Mass spectra were recorded using GCMS (gas chromatog-
raphy-mass spectrometry) on the Shimadzu Q.P.-2010 Plus (Microanalytical center, Ain 
shams University), using UV light. Spectrometer spins on a Bruker DPX 400 MHz Spectro 
spins were used to record the 1HNMR (500 MHz, DMSO-d6) and 13CNMR (125 MHz, Chlo-
roform-d) spectra. Chemical shift (d) values were stated in parts per million (ppm) using 
internal standard tetramethylsilane. The D2O exchange confirmed the exchangeable pro-
tons (OH and NH). LC-MS/MS (PerkinElmer) was used to record the mass spectra, pre-
sented as m/z. Elemental analyses were achieved at Ain Shams University on an elemen-
tary analysis system by using a PerkinElmer 240 analyzer. The purity of synthesized com-
pounds, as well as the progress of the reaction, was assessed by ascending thin-layer chro-
matography (TLC) (silica gel Fluka, 706, 43–50 E.A.) by using the methanol/chloroform 
(9:1 v/v) and methylene chloride/chloroform (4:1 v/v) combination as the solvent system. 
Figure 9. The outputs generated from 100 ns MD simulations with (A) illustration of the changes in
the RMSD values for the three studied systems, and (B) changes in the Rg values. (C) Graph depicting
the variation in the number of hydrogen bonds between HSA and docked inhibitors. ( ) r es
i t fl
Furthermore, we inferr the bondi g patterns from the hydrogen bonding and the
alculated distances between the HSA and the studied systems. Inhibitor 5 showed the
highest number of H-bonds of four with HSA, and inhibitors 4 and 3 showed three and two
bonds, respectively (Figure 9C). One can also observe similar behavior for the calculated
distances with the least distance of around 0.15 nm between the HSA and inhibitor 5
(Figure 9D). Moreover, the MM/PBSA-based protocols were used to calculate the diverse
interaction energies between the HSA and the studied inhibitors. Inhibitor 3 showed the
highest binding energy of 375.922 kJ/mol, followed by inhibitors 5 and 4a (Table 13).
These observations validated the experimental findings and showed that the studied
inhibitors favorably bonded to the HSA proteins and may result in the limitation of the
cancer proliferation by inhibiting the activities of the proteins.
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3. Methodology
3.1. Chemistry
All reactions were carried out with the exclusion of moisture. All solvents were
dried. All melting points were uncorrected. The IR spectra were recorded as potas-
sium bromide pellets on an Aldrich FT-IR spectrometer (Central lab at Faculty of Science,
Benha, Ain Shams, and Cairo universities). Mass spectra were recorded using GCMS (gas
chromatography-mass spectrometry) on the Shimadzu Q.P.-2010 Plus (Microanalytical
center, Ain shams University), using UV light. Spectrometer spins on a Bruker DPX 400
MHz Spectro spins were used to record the 1HNMR (500 MHz, DMSO-d6) and 13CNMR
(125 MHz, Chloroform-d) spectra. Chemical shift (d) values were stated in parts per
million (ppm) using internal standard tetramethylsilane. The D2O exchange confirmed
the exchangeable protons (OH and NH). LC-MS/MS (PerkinElmer) was used to record
the mass spectra, presented as m/z. Elemental analyses were achieved at Ain Shams
University on an elementary analysis system by using a PerkinElmer 240 analyzer. The
purity of synthesized compounds, as well as the progress of the reaction, was assessed by
ascending thin-layer chromatography (TLC) (silica gel Fluka, 706, 43–50 E.A.) by using the
methanol/chloroform (9:1 v/v) and methylene chloride/chloroform (4:1 v/v) combination
as the solvent system.
3.1.1. Synthesis of 2a-b by the Action of Urea and Thiourea on Oxazine Derivative 1a
A solution of 1a (0.01 mole) and urea or thiourea (0.01 mole) in 30 mL of n-butanol




2a:yellow solid, m.p. 98–100 ◦C, yield 76%, IR (KBr) υ cm−1 1720–1710 cm−1 (CO),
2230–2220 (CN), and 3380–3370 (NH). 1H NMR δ: 7.49–7.41 (m, 2H), 7.36–7.27 (m, 3H),
7.04 (d, J = 0.9 Hz, 1H), 5.35 (d, J = 6.0 Hz, 2H).13C NMR δ: 165.92, 162.30, 161.01, 159.31,
154.69, 134.59, 133.22, 129.09, 128.30 (d, J = 15.7 Hz), 126.96, 122.78, 117.42, 82.79, 50.51,
38.77. Elemental analysis calculated for C22H9N5O5Br4 (743); C:35.6; H:1.2; N:9.4. Found
C:35; H:1; N: 9%.
3.1.3. 2-(Tetrabromophthalimidomethyl-6-Phenyl-5-Cyano-1,3-Oxazino[4,5-e]-1,3-
Pyrimidine-3-[H]-2-Thione-4-One (2b)
2b:brown solid, m.p. 150–152 ◦C, yield 79%, IR (KBr) υ cm−1 1720–1710 (CO), 2230–
2220 (CN), 1200–1190 (CS) and 3380–3370 (NH). 1H NMR δ: 7.49–7.41 (m, 2H), 7.36–7.27
(m, 3H), 7.04 (d, J = 0.9 Hz, 1H), 5.35 (d, J = 6.0 Hz, 2H).13C NMR δ: 182.32, 173.77, 165.92,
159.90, 158.70, 134.59, 133.15, 129.09, 128.37, 128.24, 126.91, 122.78, 118.70, 81.87, 50.49, 38.77.
Elemental analysis calculated for C22H9N5O4SBr4 (759); C: 34.8; H: 1.2; N: 9.2. Found C:
34.2; H: 1.1; N: 8.9%.
Molecules 2021, 26, 5482 19 of 24
3.1.4. Synthesis of 2-(Tetrabromophalimidmethyl)-6-Phenyl-5-Yano-1,3-Oxazino[4,5-d]-1,2-
Pyrazole2[H]-3-One (3)
A solution of 1a (0.01 mole) and hydrazine hydrate (0.01 mole) in 30 mL of n-butanol
was refluxed for 5 h. The solid formed was collected and crystallized from benzene.
3:brown solid, m.p. 136–138 ◦C, yield 81%, IR (KBr) υ cm−1 1715 cm−1 as the presence
of CO, 2205 CN, and 3154–3350 NH, 1H NMR δ: 8.01 (s, 1H), 7.40–7.34 (m, 2H), 7.34–7.28
(m, 3H), 6.72 (d, J = 0.8 Hz, 1H), 4.72 (d, J = 6.0 Hz, 2H). 13C NMR δ: 167.13, 166.73, 159.97,
156.78, 142.21, 133.23, 131.92, 130.54, 129.00, 128.43, 128.38, 126.63, 124.96, 120.94, 120.87,
120.49, 80.82, 47.77, 37.81. Elemental analysis calculated for C21H9N5O4Br4 (715); C: 35.3;
H: 1.3; N: 9.8. Found C: 34.4; H: 1.1; N: 9.5%.
3.1.5. Synthesis of 4a-b by the Action of Urea and Thiourea on Oxazine Derivative 1b
A solution of 1b (0.01 mole) and urea or thiourea (0.01 mole) in 30 mL of n-butanol was
refluxed for 5 h. The solid formed was crystallized from the proper solvent to give 4a-b.
3.1.6. Synthesis of 2-(Tetrabromophthalimidomethyl-6-Phenyl-5-Cyano-1,3-Oxazino[4,5-e]-
1,3-Pyrimidine-3-[H]-2-One-5-Imide (4a)
4a:brown solid, m.p. 80–82 ◦C, crystalized from benzene, yield 72%, IR (KBr) υ cm−1
2260 (CN), 3378 (NH) and 1780,1720 (CO). 1H NMR δ: 9.63 (s, 1H), 8.08 (s, 1H), 7.44–7.37
(m, 2H), 7.35–7.28 (m, 3H), 7.01 (d, J = 0.9 Hz, 1H), 5.35 (d, J = 6.0 Hz, 2H). 13C NMR δ:
166.53, 166.15, 163.32, 161.16, 154.22, 151.02, 140.50, 134.79 (d, J = 6.0 Hz), 134.13, 128.30 (d,
J = 16.2 Hz), 126.88, 125.55, 123.97, 120.27, 119.71, 82.24, 40.21, 38.63. Elemental analysis
calculated for C22H10N6O4Br4 (742); C: 35.6; H: 1.4; N: 11.4. Found C: 35.1; H: 1.2; N: 11%.
3.1.7. 2-(Tetrabromophthalimidomethyl-6-Phenyl-5-Cyano-1,3-Oxazino[4,5-e]-1,3-
Pyrimidine-3-[H]-2-Thione-4-Imide (4b)
4b:brown solid, m.p. 145–147 ◦C, crystalized from ethanol, yield 83%, IR (KBr) υ cm−1
1278 cm−1 (CS), 2260 (CN), 3378 (NH), and 1780,1720 (CO). 1H NMR δ: 9.60 (s, 1H), 8.08
(s, 1H), 7.44–7.37 (m, 2H), 7.35–7.28 (m, 3H), 7.01 (d, J = 0.9 Hz, 1H), 5.35 (d, J = 6.0 Hz,
2H). 13C NMR δ: 180.40, 175.52, 166.53, 166.15, 160.35, 150.64, 140.50, 134.79 (d, J = 6.0
Hz), 134.12, 128.30 (d, J = 16.2 Hz), 126.88, 125.55, 123.34, 120.27, 119.71, 81.86, 48.24, 38.72.
Elemental analysis calculated for C22H10N6O4Br4 (758); C: 34.9; H: 1.3; N: 11.1. Found C:
34.2; H: 1.2; N: 10. 9%.
3.1.8. Synthesis of 2-(Tetrabromophalimidmethyl)-6-Phenyl-5-Yano-1,3-Oxazino[4,5-d]-1,2-
Pyrazole2[H]-3-Imide (5)
A solution of 1b (0.01 mole) and hydrazine hydrate (0.01 mole) in 30 mL of n-butanol
was refluxed for 5 h. Then, the crude was collected and crystallized from ethanol.
5:brown solid, m.p. 90–92 ◦C, yield 75%, IR (KBr) υ cm−1, 3350–3310 (NH), 2360 (CN),
1780, 1730 (CO), 1H NMR δ: 7.40–7.35 (m, 2H), 7.35–7.28 (m, 3H), 6.70 (d, J = 1.0 Hz, 1H),
5.02 (d, J = 7.0 Hz, 2H), 4.26 (t, J = 1.0 Hz, 2H), 3.01 (d, J = 2.0 Hz, 2H). 13C NMR δ: 172.60,
168.52, 159.98, 158.67, 131.92, 129.00, 128.59–128.30 (m), 128.08, 126.63, 120.49, 80.50, 47.78,
38.63, 35.63, 32.14. Elemental analysis calculated for C21H10N6O3Br4 (714); C: 35.3; H: 1.4;
N: 11.8. Found C: 34.9; H: 1.2; N: 11.2%.
3.2. Biological Studies
3.2.1. Antimicrobial Studies
All investigations were executed at the Biology department, Faculty of Science, Benha
University, Egypt. The antimicrobial activities of all the synthesized molecules were deter-
mined in vitro, using the hole-plate and filter disc methodologies [33–36]. The investigated
compounds were dissolved in 10% acetone (v/v). The width of the inhibition zone in-
dicated the potency of the antimicrobial activity: (-) no antimicrobial activity, (+) mild
activity with the diameter of the zones equal to (0.5–0.7 cm), (++) moderate activity with the
diameter of the zones equal to (1.1–1.2 cm), and (+++) marked activity with the diameter
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of the zones equal to (1.6–1.8 cm). The results of the control samples are not included in
Table 1, as they revealed a negative response.
3.2.2. Anticancer
The cells were supplied by the Egyptian Holding Company for Biological Products and
Vaccines (VACSERA) and then kept in the tissue culture unit. The growth of the cells was
affected in RPMI-1640 medium, supplemented with 10% heat-inactivated FBS, 50 units/mL
of penicillin, and 50 mg/mL of streptomycin, and maintained in a humidified atmosphere
with 5% carbon dioxide [37,38]. The cells were maintained as monolayer cultures by serial
sub-culturing, with cell culture reagents obtained from Lonza (Basel, Switzerland). The
antitumor activities of the complexes were assessed against three cell lines MCF-7 for breast
cancer, Ovcar-3 for ovarian cancer, and Hela for cervical cancer. In addition, all the results
obtained were compared and validated to the LCC-MK2 normal cell line. In the literature,
the sulforhodamine B (SRB) assay method was applied to determine the cytotoxicity, as
described in [39]. Exponentially growing cells were collected using 0.25% Trypsin-EDTA
and seeded in 96-well plates at 1000–2000 cells/well in RBMI-1640-supplemented medium.
The cells were kept in the medium for 24 h and then incubated for 3 days with various
concentrations of the copper complexes. Following 3 days of treatment, the cells were
fixed with 10% trichloroethanoic acid for 1 h at 4 ◦C. Wells were stained for 10 min at
room temperature with 0.4% SRBC dissolved in 1% acetic acid. The plates were air-dried
for 24 h, and the dye was dissolved in Tris-HCl for 5 min with shaking at 1600 rpm. An
ELISA microplate reader (ChroMate-4300, FL, USA) was used to assess each well’s optical
density (O.D.) at 564 nm. The IC50 values were calculated from a Boltzmann sigmoidal
concentration-response curve using the nonlinear regression fitting models (Graph Pad,
Prism Version 9).
3.3. Computational Studies
3.3.1. Molecular Docking Studies with MOE
Molecular operation environment software (MOE) was utilized to dock the complexes
toward the MCF-7 breast (PDB = 3 KRR), HeLa caspase3 (PDB = V266), and ovarian cancer
targets (PDB = 3 W2S). We used the docking protocol that was described in our previous
work [13]. After the crystal structure was downloaded from the PDB www.rcsb.org (ac-
cessed on 12 July 2021), the water molecules, co-ligand, and metal ions were removed.
The final form was obtained after 3D protonation and the correction process. The MOE
site finder generated the active binding sites to create the dummy sites as the binding
pocket. The default docking parameters were triangle matcher for replacing the molecule
and London dG for rescoring the docking scores. The DFT-optimized structures of the
compounds were used to generate the best five binding poses with flexible molecules
rotation. The hydrogen bonds formed between the elastase and the investigated compound
were used to rank the binding affinity and were presented as the free binding energy
(S, kcal/mol). The higher negative values of the docking scores were presented along with
2D and 3D structures.
3.3.2. Virtual Screening and Validation
Considering the three cell lines Ovcar-3, Hela, and MCF-7 used in the experimental
procedures, the information regarding the protein targets was collected from the litera-
ture [22,23,40,41] and biological databases. The seven targets were selected for the virtual
screening (Table 3). The 3-D coordinates of Caspase-3 (PDB ID-3KRR), Human Cyclin-
Dependent Kinase 2 (CDK2, PDB ID-3QTR), Epidermal Growth Factor Receptor (EGFR,
PDB ID-1XKK), Human B-Raf Kinase (PDB ID-3SKC), Human Estrogen Receptor Ligand-
Binding Domain (PDB ID-1ERE), Human Serum Albumin (HSA, PDB ID-6WUW), and
Human topoisomerase I (PDB ID-1EJ9) were collected from the database. The structures
of the protein targets were optimized using the JAGUAR module [24] utilities present
in MAESTRO (Schrödinger Release 2018-1: Maestro, Schrödinger, LLC, New York, NY,
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USA, 2018). Subsequently, the virtual screening between the target protein and studied
inhibitors was performed using Autodock vina [42]. The best-docked conformations were
statistically characterized by combining the free energy functional, the Lamarckian Genetic
Algorithm, and the empirical force field [25]. The space of the grid dimension was set
for 40 × 40 × 40 Å along with the XYZ directions with varied central coordinates, and a
maximum efficiency range was used in the parameters for the optimum results.
3.3.3. ADME and Pharmacophore Studies
The Lipinski’s rule of five (5) by Christopher A. Lipinski in 1997 is a thumb rule
for evaluating drug-likeness and determining if an inhibitor with specific biological and
pharmacological properties would be an orally active drug in the human body [21,25].
The rule states that a molecule can be orally absorbed/active if two (2) or more of these
thresholds: molecular weight (Mw) of molecule < 500, octanol/water partition coefficient
(ilog P) ≤ 5, number of hydrogen bond acceptors (nHBA) ≤ 10, number of hydrogen bond
donors (nHBD) ≤ 5, and topological polar surface area (TPSA) < 40 Å2), are not violated.
3.3.4. MD Simulations
After the analyses of the docking results, the complexes of 3a, 4a, and 5, which were
induced with HSA inhibitor, were selected for further studies using the GROMACS 2018-2
package [43], which was used to study their conformational dynamics under explicit water
conditions for a 100 ns time scale. The OPLS-AA force field [44] was used to generate
the topologies of the HSA protein in the docked complexes. The LigParGen server [45]
generated the same force field potentials for the complex inhibitors. Afterward, the systems
were immersed in the SPC/E water model [46,47] and neutralized by adding counter
NA and CL ions. The further processing involved energy minimization using steepest
descent and conjugate gradient algorithms, with a convergence criterion of 0.005 kcal/mol.
The minimized systems were subjected to positions restraining and then equilibrated
under NVT (constant volume) and NPT (constant pressure) ensemble conditions, each at
a 100 ps time scale. The temperature of 300 K was maintained for the system using the
Berendsen weak coupling method, and the pressure of 1 bar was maintained utilizing the
Parrinello-Rahman barostat in the equilibration stage.
Furthermore, the final production stage was carried out using the LINCS algorithm.
The generated trajectories were analyzed for the changes in the pattern of protein-inhibitor
distances, H-bonds, RMSD, and Rg. Finally, the molecular mechanics Poisson-Boltzmann
surface area (MM-PBSA) protocols implemented in the g_mmpbsa package [47] were used
to calculate binding free energy between the HSA and inhibitors.
4. Conclusions
The present research strengthens the applicability of these compounds by encouraging
anticancer and antibacterial drugs that could help medicinal chemists and pharmaceuticals
further design and synthesize more effective drug candidates. Furthermore, with the
collected and interpreted results, from oxazinethione, one can synthesize new pyrazoles
and pyrimidine derivatives. According to ADME studies and molecular dynamics studies,
compound 5 is the most potent for biological investigations, especially for Hela and ovarian
cancer, with good pharmacokinetic properties showing high gastrointestinal absorption.
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S. aureus Staphylococcus aureus
F. moniliform Fusarium moniliform
PDB Protein Data Bank
ADME absorption, distribution, metabolism, and excretion
References
1. Abdellattif, M.H.; Ali, O.A.; Arief, M.M.H.; Hussien, M.A. One-pot Synthesis of Novel Derivatives of Oxadiazine-4-thione, and
its Antibacterial Activity, and Molecular Modeling Studies. Curr. Org. 2020, 17, 1–13. [CrossRef]
2. Sondhi, S.M.; Johar, M.; Rajvanshi, S.; Dastidar, S.G.; Shukla, R.; Raghubir, R.; Lown, J.W. Anticancer, Anti-inflammatory and
Analgesic Activity Evaluation of Heterocyclic Compounds Synthesized by the reaction of 4-Isothiocyanato-4-methylpentan-2-one
with Substituted o-Phenylenediamines, o-Diaminopyridine and (Un)Substituted o. Aust. J. Chem. 2001, 54, 69–74. [CrossRef]
3. Asif, M.; Imran, M. Pharmacological Profile of Oxazine and its Derivatives: A Mini Review. Int. J. New. Chem. 2020, 7, 60–73. [CrossRef]
4. Tajima, H.; Kimoto, H.; Taketo, Y.; Taket, A. Effects of Synthetic Hydroxy Isothiocyanates on Microbial Systems. Biosci. Biotechnol.
Biochem. 1998, 62, 491–495. [CrossRef] [PubMed]
5. Elnagdi, M.H.; Fahmy, S.M.; Elmoghayar, M.R.H.; Negm, A.M. Pyrimidine Derivatives and Related Compounds, IX/Preparation
of 5-Aminopyrazolo[1,5-a]pyrimidines and of Oxazino[4,5:5,6]pyrazolo[1,5-a]pyrimidines, a New Ring System. Z. Nat. B 1977,
32, 1478–1481. [CrossRef]
6. Vinita, S.; Nitin, C.; Ajay, K.A. Significance and Biological Importance of Pyrimidine in the Microbial World. Int. J. Med. Chem.
2014, 2014, 31. [CrossRef]
7. Pyrimidine Derivatives. Available online: https://go.drugbank.com/categories/DBCAT002332 (accessed on 12 July 2021).
8. Sammar, A.; Bandar, A.B.; Abdellattif, M.H.; Abdul-Hamid, E.; Mariusz, J.; Mark, G.H.; Mostafa, A.H. Effect of Net Charge on
DNA-Binding, Protein-Binding and Anticancer Properties of Copper(I) Phosphine-Diimine Complexes. J. Inorg. Organomet.
Polym. Mater. 2021, 1–10. [CrossRef]
9. Ajmal, R.; Rajendra, B.; Dongre, S.; Aabid, H.; Gowhar, S.; Naikoo, A.; Hassan, I.U. Computational analysis for antimicrobial
active pyrano[2,3-d]pyrimidine derivatives on the basis of theoretical and experimental ground. J. Taibah Univ. Sci. 2016, 20,
19–25. [CrossRef]
10. Bandar, A.B.; Jalal, H.A.; Bambar, D.; Abdul-Hamid, E.; Mariusz, J.; Magda, H.A.; Mostafa, A.H. Synthesis, Structural Studies,
and Anticancer Properties of CuBr(PPh3)2(4,6-Dimethyl-2-Thiopyrimidine-κS. Crystals 2021, 11, 688. [CrossRef]
11. Helmy, M.M.; Abdellattif, M.H.; Eldeab, H.A. New Methodology for Synthesis of Coumarin Derivatives as Potent Antimicrobial
Agents. Int. J. Adv. Pharm. Biol. Chem. 2014, 3, 983–990.
12. Bhatt, H.B.; Sharma, S. Synthesis and antimicrobial activity of pyrazole nucleus containing 2-thioxothiazolidin-4-one derivatives.
Arab. J. Chem. 2017, 10, S1590–S1596. [CrossRef]
13. Abdellattif, M.H.; Hussien, M.A.; Alzahrani, E. New Approaches of 4-aryl-2-hydrazinothiazole derivatives synthesis, molecular
Docking and biological evaluations. Int. J. Pharm. Sci. Res. 2018, 9, 1000–1019.
14. Barakat, A.; Al-Majid, A.M.; Soliman, S.M.; Lotfy, G.; Ghabbour, H.A.; Fun, H.K.; Wadood, A.; Warad, I.; Sloop, J.C. New diethyl
ammonium salt of thiobarbituric acid derivative: Synthesis, molecular structure investigations and docking studies. Molecules
2015, 20, 20642–20658. [CrossRef] [PubMed]
15. McNutt, M.C.; Kwon, H.J.; Chen, C.; Chen, J.R.; Horton, J.D.; Lagace, T.A. Antagonism of secreted PCSK9 increases low density
lipoprotein receptor expression in HepG2 cells. J. Biol. Chem. 2009, 284, 10561–10570. [CrossRef]
16. Mashat, K.H.; Babgi, B.A.; Hussien, M.A.; Arshad, M.N.; Abdellattif, M.H. Synthesis, structures, DNA-binding and anticancer
activities of some copper(I)-phosphine complexes. Polyhedron 2019, 158, 164–172. [CrossRef]
17. Subudhi, B.B.; Chattopadhyay, S.; Mishra, P.; Kumar, A. Current strategies for inhibition of chikungunya infection. Viruses 2018,
10, 235. [CrossRef] [PubMed]
Molecules 2021, 26, 5482 23 of 24
18. El-Hashash, M.A.; Rizk, S.A.; El-Sayed, A.A. Ultrasonic and solvent free synthesis of regioselective diastereomeric adducts and
heterocyclic products as antibacterial agent. J. Adv. Chem. 2017, 13, 6106–6117.
19. Hegelund, F.; Larsen, R.W.; Palmer, M.H. The vibration spectrum of thiazole between (600–1400 cm−1) revisited, a combined high
resolution infrared and theoretical study. J. Mol. Spectrosc. 2007, 244, 63–78. [CrossRef]
20. Arikan, N.; Sumengen, D.; Dulger, B. Syntheisi and antimicrobial activity of 1,2,4 oxadiazine-5-one, 6-ones, and 5-thiones. Turk. J.
Chem. 2008, 32, 147–155.
21. Trott, O.; Olson, A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient
optimization and multithreading. J. Comput. Chem. 2010, 31, 455–461. [CrossRef]
22. Belay, Z.S.; Sonia, K.; Pankaj, T.; Paratpar, S.; Neetu, K.T. Molecular Docking, synthesis and anticancer activity of thiosemicar-
bazone derivatives against MCF-7 human breast cancer cell line. Life Sci 2021, 273, 119305.
23. Zhang, F.; Zhang, H.; Wang, F. EGFR inhibition studies by hybrid scaffolds for their activity against ovarian cancer. J. Balk. Union
Oncol. 2016, 21, 1482–1490.
24. Bochevarov, A.D.; Harder, E.; Hughes, T.F. Jaguar: A high-performance quantum chemistry software program with strengths in
life and materials sciences. Int. J. Quantum Chem. 2013, 113, 2110–2142. [CrossRef]
25. Di, L.; Kerns, E.H. Drug-Like Properties: Concepts, Structure Design and Methods from ADME to Toxicity Optimization; Elsevier:
London, UK, 2016.
26. Bala, S.; Kamboj, S.; Kajal, A.; Saini, V.; Prasad, D.N. 1,3,4-oxadiazole derivatives: Synthesis, characterization, antimicrobial
potential, and computational studies. BioMed Res. Int. 2014, 2014, 172791. [CrossRef] [PubMed]
27. Mamoru, K.; Yusuke, Y.; Hiromune, A.; Hideharu, I. Synthesis of 1,3-Selenazetidines and 4H-1,3,5-Oxadiazines Using Acyl
Isoselenocyanates. Heterocycles 2006, 68, 1267–1273.
28. Helmy, M.M.; Moustafa, M.H.; Eldeab, H.A. Microwave-Assisted Synthesis of New Series Some Acetyl Coumarin Derivatives
and Studying of Some their Pharmacological Activities. J. Pharm. Sci. Res. 2015, 7, 83–88.
29. Magda, H.A. Synthesis of Some Novel Compounds of Saccharinyl Acetic Acid Containing Nucleus and Evaluation of Their
Biological Activities as Antimicrobial. Orient. J. Chem. 2016, 32, 567–574.
30. Muanza, D.N.; Kim, B.W.; Euler, K.L.; Williams, L. Antibacterial and antifungal activities of nine medicinal plants of Zaire. Int. J.
Pharmacog. 1994, 32, 337–345. [CrossRef]
31. Pezzuto, J.M.; Che, C.-T.; McPherson, D.D.; Zhu, J.-P.; Topcu, G.; Erdelmeier, C.A.J.; Cordell, G.A. DNA as afnity probe useful in
the detection and isolation of biologically active natural products. J. Nat. Prod. 1991, 54, 1522–1530. [CrossRef]
32. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J.; Bokesch, H.; Kenney, S.; Boyd, M.R. New
colorimetric cytotoxicity as anticancer drug screening. J. Natl. Cancer Inst. 1990, 82, 1107–1112. [CrossRef]
33. Ekici, O.D.; Li, Z.Z.; Campbell, A.J.; James, K.E.; Asgian, J.L.; Mikolajczyk, J.; Salvesen, G.S.; Ganesan, R.; Jelakovic, S.; Grütter,
M.G.; et al. Design, synthesis, and evaluation of aza-peptide Michael acceptors as selective and potent inhibitors of caspases-2, -3,
-6, -7, -8, -9, and -10. J. Med. Chem. 2006, 49, 5728–5749. [CrossRef]
34. Ernst, S.; Stephane, B.; Riazul, A.; Mathew, P.M.; Andreas, B.; Han, H.; Rawle, F.; Ramappa, C.; Sudhakar, J.; Aslamuzzaman, K.;
et al. Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. J. Med. Chem. 2013, 56,
3768–3782.
35. Edgar, R.W.; Anne, T.T.; Octerloney, B.M.D.; Derek, Y.; Anne, H.; Scott, H.D.; Byron, E.; Christopher, P.; Earnest, H. A unique
structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation,
inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004, 64, 6652–6659.
36. Steve, W.; Li, R.; Kateri, A.A.; Ellen, R.L.; Ignacio, A.; Bruno, A.; Alex, J.B.; Edna, F.C.; Victoria, D.; Bainian, F.; et al. Pyrazolopyri-
dine inhibitors of B-RafV600E. Part 2: Structure–activity relationships. Bioorgan. Med. Chem. Lett. 2011, 21, 5533–5537.
37. Brzozowski, A.M.; Pike, A.C.W.; Dauter, Z.; Hubbard, R.E.; Bonn, T.; Engström, O.; Öhman, L.; Greene, G.L.; Gustafsson, J.;
Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389, 753–758. [CrossRef]
38. Mateusz, P.C.; Adam, M.B.; Ettore, J.R.; Nikhil, R.T.; Taber, S.M.; Isabella, K.B.; Kelley, E.M.; John, H.B.; Wladek, M.; Peter, W.;
et al. Structure of the Complex of an Iminopyridinedione Protein Tyrosine Phosphatase 4A3 Phosphatase Inhibitor with Human
Serum Albumin. Mol. Pharmacol. 2020, 98, 648–657.
39. Redinbo, M.R.; Champoux, J.J.; Hol, W.G.J. Novel Insights into Catalytic Mechanism from a Crystal Structure of Human
Topoisomerase I in Complex with DNA. Biochemistry 2000, 39, 6832–6840. [CrossRef]
40. Ibrahim, A.A.-S.; Naglaa, I.A.-A.; Adel, S.E.-A.; Magda, A.A.E.-S.; Amer, M.A.; Mahmoud, B.E.-A.; Alaa, A.-M.A.-A. Antitumor
evaluation and molecular docking study of substituted 2-benzylidenebutane-1,3-dione, 2-hydrazonobutane-1,3-dione and
trifluoromethyl-1H-pyrazole analogues. J. Enzym. Inhib. Med. Chem. 2015, 30, 679–687.
41. Somaia, S.A.E.-K.; Yasmin, M.S.; Ahmed, M.E.K.; Tamer, M.A. New thiazol-hydrazono-coumarin hybrids targeting human
cervical cancer cells: Synthesis, CDK2 inhibition, QSAR and molecular docking studies. Bioorganic Chem. 2019, 86, 80–96.
42. Zhang, P.; Xu, S.; Zhu, Z.; Xu, J. Multi-target design strategies for the improved treatment of Alzheimer’s disease. Eur. J. Med.
Chem. 2019, 176, 228–247. [CrossRef]
43. David, V.; Der, S.; Erik, L.; Berk, H.; Gerrit, G.; Alan, E.M.; Herman, J.C.B. GROMACS: Fast, flexible, and free. J. Comput. Chem.
2005, 26, 1701–1718.
44. Robertson, M.J.; Tirado-Rives, J.; Jorgensen, W.L. Improved Peptide and Protein Torsional Energetics with the OPLSAA Force
Field. J. Chem. Theory Comput. 2015, 11, 3499–3509. [CrossRef] [PubMed]
Molecules 2021, 26, 5482 24 of 24
45. Leela, S.D.; Israel, C.V.; Julian, T.-R.; William, L.J. LigParGen web server: An automatic OPLS-AA parameter generator for organic
ligands. Nucleic Acids Res. 2017, 45, W331–W336.
46. Zielkiewicz, J. Structural properties of water: Comparison of the SPC, SPCE, TIP4P, and TIP5P models of water. J. Chem. Phys.
2005, 123, 104501. [CrossRef]
47. Kumari, R.; Kumar, R.; Lynn, A. g_mmpbsa—A GROMACS tool for high-throughput MM-PBSA calculations. J. Chem. Inf. Model.
2014, 54, 1951–1962. [CrossRef] [PubMed]
